MKI67 and neoplasm: Combination of adavosertib with anti-PD-L1 resulted in approx. 2-fold increased numbers of tumour infiltrating CD8+ T cells and significantly increased Ki67 expression of tumour infiltrating T cells over vehicle or anti-PD-L1 alone.